Other languages Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-28 pm EDT			5-day change	1st Jan Change
25.13 ^USD	-1.76%		-3.46%	-21.07%

Jun. 28	Would you like some more inflation?
Jun. 28	Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	MT

Other languages

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	Jun. 28
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	Jun. 28
En Direct des Marchés : Renault, L'Oréal, Schneider Electric, Atos, Nokia, Meta Platforms...	Jun. 28
Vous reprendrez bien un peu d'inflation ?	Jun. 28
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	Jun. 28
Bolsa de Madrid: ¿Le apetece un poco más de inflación?	Jun. 28
Genmab Closes DKK3.5 Billion Share Buyback Early	Jun. 28
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	Jun. 27
Genmab Wins US Approval for Follicular Lymphoma Treatment	Jun. 27
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	Jun. 26
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	Jun. 26
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study	Jun. 03
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin	Jun. 03
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial	Jun. 03
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial	Jun. 03
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma	Jun. 02
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab	Jun. 01
Genmab A/S Reaffirms Financial Guidance for 2024	May. 21
Genmab A/S completed the acquisition of ProfoundBio, Inc.	May. 20
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'	May. 15

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT